George O Agogo1, Christine M Ramsey2, Danijela Gnjidic3, Daniela C Moga4, Heather Allore1. 1. Department of Internal Medicine,Yale School of Medicine,New Haven,Connecticut,USA. 2. Yale Center for Medical Informatics,Yale School of Medicine,New Haven,Connecticut,USA. 3. Faculty of Pharmacy and Charles Perkins Centre,University of Sydney,Sydney,New South Wales,Australia. 4. Department of Pharmacy Practice and Science,College of Pharmacy,University of Kentucky,Lexington,Kentucky,USA.
Abstract
ABSTRACTBackground:Longitudinal studies of older adults are characterized by high dropout rates, multimorbid conditions, and multiple medication use, especially proximal to death. We studied the association between multiple medication use and incident dementia diagnoses including Alzheimer's disease (AD), vascular dementia (VD), and Lewy-body dementia (LBD), simultaneously accounting for dropout. METHODS: Using the National Alzheimer's Coordinating Center data with three years of follow-up, a set of covariate-adjusted models that ignore dropout was fit to complete-case data, and to the whole-cohort data. Additionally, covariate-adjusted joint models with shared random effects accounting for dropout were fit to the whole-cohort data. Multiple medication use was defined as polypharmacy (⩾ five medications), hyperpolypharmacy (⩾ ten medications), and total number of medications. RESULTS: Incident diagnoses were 2,032 for AD, 135 for VD, and 139 for LBD. Percentages of dropout at the end of follow-up were as follows: 71.8% for AD, 81.5% for VD, and 77.7% for LBD. The odds ratio (OR) estimate for hyperpolypharmacy among those with LBD versus AD was 2.19 (0.78, 6.15) when estimated using complete-case data and 3.00 (1.66, 5.40) using whole-cohort data. The OR reduced to 1.41 (0.76, 2.64) when estimated from the joint model accounting for dropout. The OR for polypharmacy using complete-case data differed from the estimates using whole-cohort data. The OR for dementia diagnoses on total number of medications was similar, but non-significant when estimated using complete-case data. CONCLUSION: Reasons for dropout should be investigated and appropriate statistical methods should be applied to reduce bias in longitudinal studies among high-risk dementia cohorts.
ABSTRACTBackground:Longitudinal studies of older adults are characterized by high dropout rates, multimorbid conditions, and multiple medication use, especially proximal to death. We studied the association between multiple medication use and incident dementia diagnoses including Alzheimer's disease (AD), vascular dementia (VD), and Lewy-body dementia (LBD), simultaneously accounting for dropout. METHODS: Using the National Alzheimer's Coordinating Center data with three years of follow-up, a set of covariate-adjusted models that ignore dropout was fit to complete-case data, and to the whole-cohort data. Additionally, covariate-adjusted joint models with shared random effects accounting for dropout were fit to the whole-cohort data. Multiple medication use was defined as polypharmacy (⩾ five medications), hyperpolypharmacy (⩾ ten medications), and total number of medications. RESULTS: Incident diagnoses were 2,032 for AD, 135 for VD, and 139 for LBD. Percentages of dropout at the end of follow-up were as follows: 71.8% for AD, 81.5% for VD, and 77.7% for LBD. The odds ratio (OR) estimate for hyperpolypharmacy among those with LBD versus AD was 2.19 (0.78, 6.15) when estimated using complete-case data and 3.00 (1.66, 5.40) using whole-cohort data. The OR reduced to 1.41 (0.76, 2.64) when estimated from the joint model accounting for dropout. The OR for polypharmacy using complete-case data differed from the estimates using whole-cohort data. The OR for dementia diagnoses on total number of medications was similar, but non-significant when estimated using complete-case data. CONCLUSION: Reasons for dropout should be investigated and appropriate statistical methods should be applied to reduce bias in longitudinal studies among high-risk dementia cohorts.
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: Elaine D Eaker; Susan F Mickel; Po Huang Chyou; Nancy J Mueller-Rizner; Joshua P Slusser Journal: Ann Epidemiol Date: 2002-01 Impact factor: 3.797
Authors: Danijela Gnjidic; Sarah N Hilmer; Fiona M Blyth; Vasi Naganathan; Louise Waite; Markus J Seibel; Andrew J McLachlan; Robert G Cumming; David J Handelsman; David G Le Couteur Journal: J Clin Epidemiol Date: 2012-06-27 Impact factor: 6.437
Authors: John C Morris; Sandra Weintraub; Helena C Chui; Jeffrey Cummings; Charles Decarli; Steven Ferris; Norman L Foster; Douglas Galasko; Neill Graff-Radford; Elaine R Peskind; Duane Beekly; Erin M Ramos; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2006 Oct-Dec Impact factor: 2.703
Authors: Terri R Fried; John O'Leary; Virginia Towle; Mary K Goldstein; Mark Trentalange; Deanna K Martin Journal: J Am Geriatr Soc Date: 2014-12 Impact factor: 5.562
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Danijela Gnjidic; George O Agogo; Christine M Ramsey; Daniela C Moga; Heather Allore Journal: J Gerontol A Biol Sci Med Sci Date: 2018-09-11 Impact factor: 6.053
Authors: Lilah Besser; Walter Kukull; David S Knopman; Helena Chui; Douglas Galasko; Sandra Weintraub; Gregory Jicha; Cynthia Carlsson; Jeffrey Burns; Joseph Quinn; Robert A Sweet; Katya Rascovsky; Merilee Teylan; Duane Beekly; George Thomas; Mark Bollenbeck; Sarah Monsell; Charles Mock; Xiao Hua Zhou; Nicole Thomas; Elizabeth Robichaud; Margaret Dean; Janene Hubbard; Mary Jacka; Kristen Schwabe-Fry; Joylee Wu; Creighton Phelps; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2018 Oct-Dec Impact factor: 2.703